ClinicalTrials.gg
CompletedNCT05810038Updated Sep 3, 2026Results posted

A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.

A Phase 3 interventional study of Rimegepant and Placebo in Migraine, sponsored by Pfizer. Completed at 49 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
787
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.

Enrollment
13th of 32
787 · median 618
Started
2023
the only one that year
Phase 3
14 of 32
5 open now
Registered
19th of 32
by date
Lead sponsor
24 of 32
Pfizer

Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 13th largest by enrollment, is the only one that started in 2023, is one of 14 in phase 3, and was the 19th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About rimegepant

rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing rimegepant in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the effects of Rimegepant to help prevent migraine.

This study is seeking for participants who:

  • Are male and female of 18 years of age or older.
  • Have at least 1 year history of migraine .
  • Did not take any medication for migraine before the start of this study. The study will go on for around 30 weeks, including 4 Phases and 11 Visits. Participants who are selected for the study will be randomly assigned to treatment groups. After which, the participants will enter a 12-week Double-blind Treatment (DBT) Phase. After finishing the DBT Phase, some selected participants may enter a 12-week Open-label Extension (OLE) Phase. Participants will come back to the study site at the end of Week 24 for the End of Treatment (EOT) Visit. There will be a follow-up Week 2 Visit around 14 days after the EOT visit.

Participants will be asked to take 1 tablet of study medicine every other calendar day. This need to be followed regardless of whether they have a migraine on that day or not. During the OLE Phase only, if a participant has a migraine on a non-scheduled dosing day, they may take 1 tablet of Rimegepant orally disintegrating tablet (ODT) as acute treatment for their migraine, if needed, with a maximum of 1 tablet of Rimegepant per calendar day. The study team will look at how each participant is doing with the study treatment during the regular visits at the study clinic.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • Rimegepent
  • preventive treatment
  • migraine.
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.Target Population: Participant has at least 1 year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, including the following:

  1. Age of onset of migraines prior to 50 years of age
  2. Migraine attacks, on average, lasting 4 to 72 hours if untreated
  3. Per participant report, 4 to18 migraine attacks of moderate or severe intensity per month within the last 3 months prior to the Screening Visit (month is defined as 4 weeks for the purpose of this protocol)
  4. 6 or more migraine days during Observation Phase
  5. Not more than 18 headache days during the Observation Phase
  6. Ability to distinguish migraine attacks from tension/cluster headaches.
  7. Participants with for use of triptans may be included provided they meet all other study entry criteria.

Exclusion criteria

Exclusion Criteria:

  1. Participant has a history of basilar migraine or hemiplegic migraine.
  2. Participants are excluded if they have had no therapeutic response with > 2 of the 9 medication categories of preventive treatment of migraine after an adequate therapeutic trial in the past 3 years per investigator's judgement.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
787 participants (actual)

Study arms

  • Experimental
    DBT Rimegepant/OLE Rimegepant

    DBT Phase (Weeks 1 through 12): Participants will receive a single oral dose of rimegepant orally disintegrating tablet (ODT) EOD for 12 weeks. OLE Phase (Weeks 13 through 24): Participants who continue to meet study entry criteria, will enter the OLE phase and receive a single oral dose of rimegepant ODT EOD for 12 weeks. If participants have a migraine on a day that they are not scheduled to dose with rimegepant, they can take one tablet of rimegepant ODT on that calendar day to treat a migraine (as needed \[PRN\] dosing).

    Drug: Rimegepant

  • Placebo comparator
    DBT Placebo/OLE Rimegepant

    DBT Phase (Weeks 1 through 12): Participants will receive a single oral dose of placebo matching to rimegepant ODT EOD for 12 weeks. OLE Phase (Weeks 13 through 24): Participants who continue to meet study entry criteria, will enter the OLE phase and receive a single oral dose of rimegepant ODT EOD for 12 weeks. If participants have a migraine on a day that they are not scheduled to dose with rimegepant, they can take one tablet of rimegepant ODT on that calendar day to treat a migraine (PRN dosing).

    Drug: Rimegepant · Drug: Placebo

Interventions

  • Rimegepant

    Also known as: PF-07899801, BHV-3000

  • DrugPlacebo

    matching placebo

06

What researchers measure

Primary outcomes

  1. Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)

    A migraine day(MD) was defined as any calendar day participant experienced a qualified migraine headache (onset,continuation,or recurrence), per electronic diary(eDiary). A qualified migraine headache was defined as a migraine with/without aura,lasted for \>=30 minutes with \>=2 pain features (unilateral location,pulsating quality\[throbbing\],moderate/severe pain intensity,aggravated by or caused avoidance of routine physical activity \[e.g. walking/climbing stairs\]) and/or with \>=1 of the following associated symptoms (nausea and/or vomiting, both photophobia and phonophobia).The number(no.) of md per month (m) was prorated to 28 days and derived as:OP:28\*\[total no.of MD in OP analysis period\]/(total no.of efficacy data day in OP analysis period), monthly (4-week interval) on-DBT efficacy analysis period: 28\*(total no.of MD in m)/(total no. of efficacy data days in m),overall DBT in on-DBT efficacy analysis period:28\*(total no.of MD through m3)/(total no.of efficacy data day through m3).

    Time frame: OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)

Secondary outcomes

  1. Percentage of Participants With >=50% Reduction From the OP in the Number of Moderate to Severe Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)

    A MD was defined as any calendar day participant experienced a qualified migraine headache(onset,continuation,or recurrence),per eDiary. A qualified migraine headache was defined as a migraine with/without aura,lasted for \>=30 minutes with \>=2 pain features(unilateral location,pulsating quality \[throbbing\], moderate/severe pain intensity, aggravated by or caused avoidance of routine physical activity \[e.g. walking/climbing stairs\]) and/or with \>=1 of the following associated symptoms(nausea and/or vomiting, both photophobia and phonophobia).The number of MD per month was prorated to 28 days and derived as: OP: 28\*\[total number of MD in OP analysis period\]/(total number of efficacy data days in OP analysis period), monthly (4-week interval) on-DBT efficacy analysis period: 28\*(total number of MD in month)/(total number of efficacy data days in month),overall DBT in on-DBT efficacy analysis period:28\*(total number of MD through month 3)/(total no .of efficacy data days through month 3).

    Time frame: OP (screening of 4 weeks prior to randomization), DBT Phase (Weeks 1 to 12)

  2. Mean Change From the OP in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of the DBT Phase

    A MD was defined as any calendar day participant experienced a qualified migraine headache(onset,continuation,or recurrence),per eDiary. A qualified migraine headache was defined as a migraine with/without aura,lasted for \>=30 minutes with \>=2 pain features (unilateral location,pulsating quality\[throbbing\],moderate/severe pain intensity,aggravated by or caused avoidance of routine physical activity\[e.g. walking/climbing stairs\]) and/or with \>=1 of the following associated symptoms (nausea and/or vomiting, both photophobia and phonophobia).The number of MD per month was prorated to 28 days and derived as:OP:28\*\[total number of MD in OP analysis period\]/(total number of efficacy data days in OP analysis period), monthly (4-week interval) on-DBT efficacy analysis period: 28\*(total number of MD in month)/(total number of efficacy data days in month), overall DBT in on-DBT efficacy analysis period:28\*(total number of MD through month 3)/(total number of efficacy data days through month 3).

    Time frame: OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 4)

  3. Mean Change From the OP in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of the DBT Phase

    A MD was defined as any calendar day participant experienced a qualified migraine headache(onset,continuation,or recurrence),per eDiary. A qualified migraine headache was defined as a migraine with/without aura,lasted for \>=30 minutes with \>=2 pain features (unilateral location,pulsating quality\[throbbing\],moderate/severe pain intensity,aggravated by or caused avoidance of routine physical activity \[e.g. walking/climbing stairs\]) and/or with \>=1 of the following associated symptoms (nausea and/or vomiting, both photophobia and phonophobia).The number of MD per month was prorated to 28 days and derived as:OP:28\*\[total number of MD in OP analysis period\]/(total number of efficacy data days in OP analysis period), monthly (4-week interval) on-DBT efficacy analysis period: 28\*(total number of MD in month)/(total number of efficacy data days in month),overall DBT in on-DBT efficacy analysis period:28\*(total number of MD through month 3)/(total number of efficacy data days through month 3).

    Time frame: OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 9 to 12)

  4. Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQoL) Role Function-Restrictive Domain Score at Week 12 of the DBT Phase

    MSQoL:14-item instrument validated in 3 domains:restrictive role function,preventative role function and emotional function.Role function-restrictive domain consisted of 7 items that described how migraine limits one's daily social and work-related activities.Participants were required to respond to items using a 6-point scale ranging from 1-6, where 1=none of the time,2=little bit of the time,3=some of the time,4=good bit of the time,5=most of the time and 6=all of the time.Item scores were recorded using(7-original score).Raw dimension scores for restrictive role function domain were computed as a sum of recorded item scores(7-42) and rescaled from 0-100 scale such that lowest score(0) indicated poor quality of life(QOL) and highest scores(100) indicated better QOL.Change from baseline was calculated as MSQoL role function-restrictive domain score at Week 12 of DBT phase minus MSQoL role function-restrictive domain score at baseline.Data collected on Day 1 was referred to Baseline.

    Time frame: Baseline, DBT phase (Week 12)

  5. Mean Number of Acute Migraine Medication Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)

    Acute migraine-specific medication day was defined as any calendar day during which the participant took a migraine-specific medication (triptan). Acute migraine medication days were defined as either acute migraine-specific medication day or migraine day with "yes" response to the question about taking other medications to treat headache or aura. The number of migraine day per month was prorated to 28 days and derived as: OP: 28\*\[total number of migraine day in the OP analysis period\]/(total number of efficacy data days in the OP analysis period), monthly (i.e., 4-week interval) in the on-DBT efficacy analysis period: 28\*(total number of migraine day in the month)/(total number of efficacy data days in the month), overall DBT in the on-DBT efficacy analysis period: 28\*(total number of migraine day through month 3)/(total number of efficacy data days through month 3).

    Time frame: DBT phase (Weeks 1 to 12)

  6. Number of Participants With Any On-Treatment Adverse Events (AEs) by Severity During the DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AEs were graded per the common terminology criteria for adverse events (CTCAE) as grade 1 indicates mild AE, grade 2 indicates moderate AE, grade 3 indicates severe AE, grade 4 indicates life-threatening consequences and urgent intervention, and grade 5 indicates death related to AE. Number of participants who had grade 3 or 4 AEs were reported in this outcome measure.

    Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)

  7. Number of Participants With Serious Adverse Events (SAEs) On-Treatment During the DBT Phase

    An SAE was any event that met any of the criteria: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant who received rimegepant were considered an important medical event.

    Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)

  8. Number of Participants With AEs Leading to Study Intervention Discontinuation During the DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with AEs leading to discontinuation of study intervention during the DBT phase were reported.

    Time frame: DBT phase: maximum of 12 weeks

  9. Number of Participants With Any On-Treatment Grade 3 to 4 Laboratory Test Abnormalities During the DBT Phase

    Laboratory test included hematology (hemoglobin, lymphocytes, white blood cell count \[high, low\], neutrophils and platelets), serum chemistry (alkaline phosphatase \[ALP\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], albumin, bilirubin, creatine kinase \[CK\], calcium \[high, low\], glucose fasting and non-fasting \[high, low\], cholesterol \[total\], glucose \[low\], creatinine, LDL cholesterol, potassium, sodium \[high, low\], triglycerides, uric acid \[urate\] and estimated glomerular filtration rate \[eGFR\] modification of diet in renal disease \[MDRD\]) and urinalysis (urine glucose and urine protein). Laboratory abnormalities were graded according to CTCAE as grade 3 indicates severe AE, grade 4 indicates life-threatening consequences and urgent intervention. Number of participants who had non-zero grade 3 to 4 laboratory test abnormalities were reported in this outcome measure.

    Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)

  10. Number of Participants With Any On-Treatment AEs by Severity During the OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AEs were graded per the CTCAE as grade 1 indicates mild AE, grade 2 indicates moderate AE, grade 3 indicates severe AE, grade 4 indicates life-threatening consequences and urgent intervention, and grade 5 indicates death related to AE. Number of participants who had grade 3 or 4 AEs were reported in this outcome measure.

    Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)

  11. Number of Participants With SAEs On-Treatment During the OLE Phase

    An SAE was any event that met any of the criteria: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant who received rimegepant were considered an important medical event.

    Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)

  12. Number of Participants With AEs Leading to Study Intervention Discontinuation on Treatment During the OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with AEs leading to discontinuation of study intervention during the OLE phase were reported.

    Time frame: OLE phase: maximum of 12 weeks

  13. Number of Participants With Any On-Treatment Grade 3 to 4 Laboratory Test Abnormalities During the OLE Phase

    Laboratory test included hematology (hemoglobin, lymphocytes, white blood cell count \[high, low\], neutrophils and platelets), serum chemistry (ALP, ALT, AST, albumin, bilirubin, CK, calcium \[high, low\], glucose fasting and non-fasting \[high, low\], cholesterol \[total\], glucose \[low\], creatinine, LDL cholesterol, potassium, sodium \[high, low\], triglycerides, uric acid \[urate\] and eGFR MDRD) and urinalysis (urine glucose and urine protein). Laboratory abnormalities were graded according to CTCAE as grade 3 indicates severe AE, grade 4 indicates life-threatening consequences and urgent intervention. Number of participants who had non-zero grade 3 to 4 laboratory test abnormalities were reported in this outcome measure.

    Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)

  14. Number of Participants With ALT or AST Elevations >3* Upper Limit of Normal (ULN) Concurrent With Total Bilirubin (TBL) Elevations >2*ULN On-Treatment During the DBT Phase

    Number of participants with ALT or AST elevations \>3\*ULN concurrent with TBL elevations \>2\*ULN in DBT phase were reported in this outcome measure.

    Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)

  15. Number of Participants With ALT or AST Elevations >3*ULN Concurrent With TBL Elevations >2*ULN On-Treatment During the OLE Phase

    Number of participants with ALT or AST elevations \>3\*ULN concurrent with TBL elevations \>2\*ULN in OLE phase were reported in this outcome measure.

    Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)

  16. Number of Participants With Hepatic-related AEs On-Treatment During the DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with hepatic-related AEs during the DBT phase were reported.

    Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)

  17. Number of Participants With Hepatic-related AEs Leading to Study Intervention Discontinuation On-Treatment During the DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with hepatic-related AEs leading to discontinuation of study intervention during the DBT phase were reported.

    Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)

  18. Number of Participants With Hepatic-related AEs On-Treatment During the OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with hepatic-related AEs during the OLE phase were reported.

    Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)

  19. Number of Participants With Hepatic-Related AEs Leading to Study Intervention Discontinuation On-Treatment During the OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with hepatic-related AEs leading to discontinuation of study intervention during the OLE phase were reported.

    Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)

07

Results

Posted Sep 3, 2026

Participant flow

DBT Phase (12 Weeks)
Participant flow — DBT Phase (12 Weeks)
MilestoneDBT Rimegepant/ OLE RimegepantDBT Placebo/ OLE Rimegepant
Started393394
Dbt safety analysis set392394
Completed366370
Not completed2724
Withdrew: Randomized but not treated10
Withdrew: Adverse event11
Withdrew: Non-compliance with study drug02
Withdrew: Pregnancy45
Withdrew: Protocol violation21
Withdrew: Withdrawal by subject158
Withdrew: No longer met eligibility criteria43
Withdrew: Other04
OLE Phase (12 Weeks)
Participant flow — OLE Phase (12 Weeks)
MilestoneDBT Rimegepant/ OLE RimegepantDBT Placebo/ OLE Rimegepant
Started360364
Completed350354
Not completed1010
Withdrew: Adverse event10
Withdrew: Physician decision10
Withdrew: Pregnancy01
Withdrew: Withdrawal by subject58
Withdrew: Other31
Follow-up Phase (4 Weeks)
Participant flow — Follow-up Phase (4 Weeks)
MilestoneDBT Rimegepant/ OLE RimegepantDBT Placebo/ OLE Rimegepant
Started376369
Completed365364
Not completed115
Withdrew: Adverse event11
Withdrew: Pregnancy11
Withdrew: Withdrawal by subject73
Withdrew: Other20

Outcome measures

PrimaryMean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)

A migraine day(MD) was defined as any calendar day participant experienced a qualified migraine headache (onset,continuation,or recurrence), per electronic diary(eDiary). A qualified migraine headache was defined as a migraine with/without aura,lasted for \>=30 minutes with \>=2 pain features (unilateral location,pulsating quality\[throbbing\],moderate/severe pain intensity,aggravated by or caused avoidance of routine physical activity \[e.g. walking/climbing stairs\]) and/or with \>=1 of the following associated symptoms (nausea and/or vomiting, both photophobia and phonophobia).The number(no.) of md per month (m) was prorated to 28 days and derived as:OP:28\*\[total no.of MD in OP analysis period\]/(total no.of efficacy data day in OP analysis period), monthly (4-week interval) on-DBT efficacy analysis period: 28\*(total no.of MD in m)/(total no. of efficacy data days in m),overall DBT in on-DBT efficacy analysis period:28\*(total no.of MD through m3)/(total no.of efficacy data day through m3).

Time frame:
OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)
Reported as:
Least squares mean · Migraine days per month
Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)
Migraine days per monthDBT RimegepantDBT Placebo
Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)-3.64 ± 0.14-2.63 ± 0.14
Statistical analysis
  • DBT Rimegepant vs DBT Placebo · Mixed Models Analysis · p = <0.0001 · Difference in least square mean (lsm): -1.02 · 95% CI -1.40 to -0.63
SecondaryPercentage of Participants With >=50% Reduction From the OP in the Number of Moderate to Severe Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)

A MD was defined as any calendar day participant experienced a qualified migraine headache(onset,continuation,or recurrence),per eDiary. A qualified migraine headache was defined as a migraine with/without aura,lasted for \>=30 minutes with \>=2 pain features(unilateral location,pulsating quality \[throbbing\], moderate/severe pain intensity, aggravated by or caused avoidance of routine physical activity \[e.g. walking/climbing stairs\]) and/or with \>=1 of the following associated symptoms(nausea and/or vomiting, both photophobia and phonophobia).The number of MD per month was prorated to 28 days and derived as: OP: 28\*\[total number of MD in OP analysis period\]/(total number of efficacy data days in OP analysis period), monthly (4-week interval) on-DBT efficacy analysis period: 28\*(total number of MD in month)/(total number of efficacy data days in month),overall DBT in on-DBT efficacy analysis period:28\*(total number of MD through month 3)/(total no .of efficacy data days through month 3).

Time frame:
OP (screening of 4 weeks prior to randomization), DBT Phase (Weeks 1 to 12)
Reported as:
Number · Percentage of participants
Percentage of Participants With >=50% Reduction From the OP in the Number of Moderate to Severe Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)
Percentage of participantsDBT RimegepantDBT Placebo
Percentage of Participants With >=50% Reduction From the OP in the Number of Moderate to Severe Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)55.0 (50.08 to 59.99)38.4 (33.56 to 43.24)
Statistical analysis
  • DBT Rimegepant vs DBT Placebo · Mantel Haenszel · p = <0.0001 · Difference in percentage: 16.6 · 95% CI 9.65 to 23.49
SecondaryMean Change From the OP in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of the DBT Phase

A MD was defined as any calendar day participant experienced a qualified migraine headache(onset,continuation,or recurrence),per eDiary. A qualified migraine headache was defined as a migraine with/without aura,lasted for \>=30 minutes with \>=2 pain features (unilateral location,pulsating quality\[throbbing\],moderate/severe pain intensity,aggravated by or caused avoidance of routine physical activity\[e.g. walking/climbing stairs\]) and/or with \>=1 of the following associated symptoms (nausea and/or vomiting, both photophobia and phonophobia).The number of MD per month was prorated to 28 days and derived as:OP:28\*\[total number of MD in OP analysis period\]/(total number of efficacy data days in OP analysis period), monthly (4-week interval) on-DBT efficacy analysis period: 28\*(total number of MD in month)/(total number of efficacy data days in month), overall DBT in on-DBT efficacy analysis period:28\*(total number of MD through month 3)/(total number of efficacy data days through month 3).

Time frame:
OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 4)
Reported as:
Least squares mean · Migraine days per month
Mean Change From the OP in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of the DBT Phase
Migraine days per monthDBT RimegepantDBT Placebo
Mean Change From the OP in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of the DBT Phase-2.92 ± 0.17-1.92 ± 0.15
Statistical analysis
  • DBT Rimegepant vs DBT Placebo · Mixed Models Analysis · p = <0.0001 · Difference in lsm: -1 · 95% CI -1.45 to -0.55
SecondaryMean Change From the OP in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of the DBT Phase

A MD was defined as any calendar day participant experienced a qualified migraine headache(onset,continuation,or recurrence),per eDiary. A qualified migraine headache was defined as a migraine with/without aura,lasted for \>=30 minutes with \>=2 pain features (unilateral location,pulsating quality\[throbbing\],moderate/severe pain intensity,aggravated by or caused avoidance of routine physical activity \[e.g. walking/climbing stairs\]) and/or with \>=1 of the following associated symptoms (nausea and/or vomiting, both photophobia and phonophobia).The number of MD per month was prorated to 28 days and derived as:OP:28\*\[total number of MD in OP analysis period\]/(total number of efficacy data days in OP analysis period), monthly (4-week interval) on-DBT efficacy analysis period: 28\*(total number of MD in month)/(total number of efficacy data days in month),overall DBT in on-DBT efficacy analysis period:28\*(total number of MD through month 3)/(total number of efficacy data days through month 3).

Time frame:
OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 9 to 12)
Reported as:
Least squares mean · Migraine days per month
Mean Change From the OP in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of the DBT Phase
Migraine days per monthDBT RimegepantDBT Placebo
Mean Change From the OP in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of the DBT Phase-4.19 ± 0.16-3.11 ± 0.17
Statistical analysis
  • DBT Rimegepant vs DBT Placebo · Mixed Models Analysis · p = <0.0001 · Difference in lsm: -1.08 · 95% CI -1.54 to -0.62
SecondaryMean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQoL) Role Function-Restrictive Domain Score at Week 12 of the DBT Phase

MSQoL:14-item instrument validated in 3 domains:restrictive role function,preventative role function and emotional function.Role function-restrictive domain consisted of 7 items that described how migraine limits one's daily social and work-related activities.Participants were required to respond to items using a 6-point scale ranging from 1-6, where 1=none of the time,2=little bit of the time,3=some of the time,4=good bit of the time,5=most of the time and 6=all of the time.Item scores were recorded using(7-original score).Raw dimension scores for restrictive role function domain were computed as a sum of recorded item scores(7-42) and rescaled from 0-100 scale such that lowest score(0) indicated poor quality of life(QOL) and highest scores(100) indicated better QOL.Change from baseline was calculated as MSQoL role function-restrictive domain score at Week 12 of DBT phase minus MSQoL role function-restrictive domain score at baseline.Data collected on Day 1 was referred to Baseline.

Time frame:
Baseline, DBT phase (Week 12)
Reported as:
Least squares mean · Score on a scale
Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQoL) Role Function-Restrictive Domain Score at Week 12 of the DBT Phase
Score on a scaleDBT RimegepantDBT Placebo
Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQoL) Role Function-Restrictive Domain Score at Week 12 of the DBT Phase14.2 ± 0.729.9 ± 0.68
Statistical analysis
  • DBT Rimegepant vs DBT Placebo · GLM · p = <0.0001 · Difference in lsm: 4.3 · 95% CI 2.5 to 6.1
SecondaryMean Number of Acute Migraine Medication Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)

Acute migraine-specific medication day was defined as any calendar day during which the participant took a migraine-specific medication (triptan). Acute migraine medication days were defined as either acute migraine-specific medication day or migraine day with "yes" response to the question about taking other medications to treat headache or aura. The number of migraine day per month was prorated to 28 days and derived as: OP: 28\*\[total number of migraine day in the OP analysis period\]/(total number of efficacy data days in the OP analysis period), monthly (i.e., 4-week interval) in the on-DBT efficacy analysis period: 28\*(total number of migraine day in the month)/(total number of efficacy data days in the month), overall DBT in the on-DBT efficacy analysis period: 28\*(total number of migraine day through month 3)/(total number of efficacy data days through month 3).

Time frame:
DBT phase (Weeks 1 to 12)
Reported as:
Least squares mean · Acute migraine medication days per month
Mean Number of Acute Migraine Medication Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)
Acute migraine medication days per monthDBT RimegepantDBT Placebo
Mean Number of Acute Migraine Medication Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)2.29 ± 0.143.18 ± 0.16
Statistical analysis
  • DBT Rimegepant vs DBT Placebo · Mixed Models Analysis · p = =0.0001 · Difference in lsm: -0.89 · 95% CI -1.32 to -0.46
SecondaryNumber of Participants With Any On-Treatment Adverse Events (AEs) by Severity During the DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AEs were graded per the common terminology criteria for adverse events (CTCAE) as grade 1 indicates mild AE, grade 2 indicates moderate AE, grade 3 indicates severe AE, grade 4 indicates life-threatening consequences and urgent intervention, and grade 5 indicates death related to AE. Number of participants who had grade 3 or 4 AEs were reported in this outcome measure.

Time frame:
From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Any On-Treatment Adverse Events (AEs) by Severity During the DBT Phase
ParticipantsDBT RimegepantDBT Placebo
Number of Participants With Any On-Treatment Adverse Events (AEs) by Severity During the DBT Phase187
SecondaryNumber of Participants With Serious Adverse Events (SAEs) On-Treatment During the DBT Phase

An SAE was any event that met any of the criteria: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant who received rimegepant were considered an important medical event.

Time frame:
From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) On-Treatment During the DBT Phase
ParticipantsDBT RimegepantDBT Placebo
Number of Participants With Serious Adverse Events (SAEs) On-Treatment During the DBT Phase83
SecondaryNumber of Participants With AEs Leading to Study Intervention Discontinuation During the DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with AEs leading to discontinuation of study intervention during the DBT phase were reported.

Time frame:
DBT phase: maximum of 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With AEs Leading to Study Intervention Discontinuation During the DBT Phase
ParticipantsDBT RimegepantDBT Placebo
Number of Participants With AEs Leading to Study Intervention Discontinuation During the DBT Phase20
SecondaryNumber of Participants With Any On-Treatment Grade 3 to 4 Laboratory Test Abnormalities During the DBT Phase

Laboratory test included hematology (hemoglobin, lymphocytes, white blood cell count \[high, low\], neutrophils and platelets), serum chemistry (alkaline phosphatase \[ALP\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], albumin, bilirubin, creatine kinase \[CK\], calcium \[high, low\], glucose fasting and non-fasting \[high, low\], cholesterol \[total\], glucose \[low\], creatinine, LDL cholesterol, potassium, sodium \[high, low\], triglycerides, uric acid \[urate\] and estimated glomerular filtration rate \[eGFR\] modification of diet in renal disease \[MDRD\]) and urinalysis (urine glucose and urine protein). Laboratory abnormalities were graded according to CTCAE as grade 3 indicates severe AE, grade 4 indicates life-threatening consequences and urgent intervention. Number of participants who had non-zero grade 3 to 4 laboratory test abnormalities were reported in this outcome measure.

Time frame:
From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Any On-Treatment Grade 3 to 4 Laboratory Test Abnormalities During the DBT Phase
ParticipantsDBT RimegepantDBT Placebo
Lymphocytes, low11
Neutrophils11
ALT10
AST10
CK43
Glucose, low10
LDL cholesterol20
Sodium, low10
Triglycerides13
Urine glucose10
Urine protein01
SecondaryNumber of Participants With Any On-Treatment AEs by Severity During the OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AEs were graded per the CTCAE as grade 1 indicates mild AE, grade 2 indicates moderate AE, grade 3 indicates severe AE, grade 4 indicates life-threatening consequences and urgent intervention, and grade 5 indicates death related to AE. Number of participants who had grade 3 or 4 AEs were reported in this outcome measure.

Time frame:
From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Any On-Treatment AEs by Severity During the OLE Phase
ParticipantsDBT Rimegepant/ OLE RimegepantDBT Placebo/ OLE Rimegepant
Number of Participants With Any On-Treatment AEs by Severity During the OLE Phase44
SecondaryNumber of Participants With SAEs On-Treatment During the OLE Phase

An SAE was any event that met any of the criteria: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant who received rimegepant were considered an important medical event.

Time frame:
From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With SAEs On-Treatment During the OLE Phase
ParticipantsDBT Rimegepant/ OLE RimegepantDBT Placebo/ OLE Rimegepant
Number of Participants With SAEs On-Treatment During the OLE Phase51
SecondaryNumber of Participants With AEs Leading to Study Intervention Discontinuation on Treatment During the OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with AEs leading to discontinuation of study intervention during the OLE phase were reported.

Time frame:
OLE phase: maximum of 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With AEs Leading to Study Intervention Discontinuation on Treatment During the OLE Phase
ParticipantsDBT Rimegepant/ OLE RimegepantDBT Placebo/ OLE Rimegepant
Number of Participants With AEs Leading to Study Intervention Discontinuation on Treatment During the OLE Phase00
SecondaryNumber of Participants With Any On-Treatment Grade 3 to 4 Laboratory Test Abnormalities During the OLE Phase

Laboratory test included hematology (hemoglobin, lymphocytes, white blood cell count \[high, low\], neutrophils and platelets), serum chemistry (ALP, ALT, AST, albumin, bilirubin, CK, calcium \[high, low\], glucose fasting and non-fasting \[high, low\], cholesterol \[total\], glucose \[low\], creatinine, LDL cholesterol, potassium, sodium \[high, low\], triglycerides, uric acid \[urate\] and eGFR MDRD) and urinalysis (urine glucose and urine protein). Laboratory abnormalities were graded according to CTCAE as grade 3 indicates severe AE, grade 4 indicates life-threatening consequences and urgent intervention. Number of participants who had non-zero grade 3 to 4 laboratory test abnormalities were reported in this outcome measure.

Time frame:
From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Any On-Treatment Grade 3 to 4 Laboratory Test Abnormalities During the OLE Phase
ParticipantsDBT Rimegepant/ OLE RimegepantDBT Placebo/ OLE Rimegepant
Lymphocytes, low10
Neutrophils12
White blood cell count, low01
LDL cholesterol24
Sodium, high01
Triglycerides34
Urine glucose03
SecondaryNumber of Participants With ALT or AST Elevations >3* Upper Limit of Normal (ULN) Concurrent With Total Bilirubin (TBL) Elevations >2*ULN On-Treatment During the DBT Phase

Number of participants with ALT or AST elevations \>3\*ULN concurrent with TBL elevations \>2\*ULN in DBT phase were reported in this outcome measure.

Time frame:
From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With ALT or AST Elevations >3* Upper Limit of Normal (ULN) Concurrent With Total Bilirubin (TBL) Elevations >2*ULN On-Treatment During the DBT Phase
ParticipantsDBT RimegepantDBT Placebo
Number of Participants With ALT or AST Elevations >3* Upper Limit of Normal (ULN) Concurrent With Total Bilirubin (TBL) Elevations >2*ULN On-Treatment During the DBT Phase00
SecondaryNumber of Participants With ALT or AST Elevations >3*ULN Concurrent With TBL Elevations >2*ULN On-Treatment During the OLE Phase

Number of participants with ALT or AST elevations \>3\*ULN concurrent with TBL elevations \>2\*ULN in OLE phase were reported in this outcome measure.

Time frame:
From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With ALT or AST Elevations >3*ULN Concurrent With TBL Elevations >2*ULN On-Treatment During the OLE Phase
ParticipantsDBT Rimegepant/ OLE RimegepantDBT Placebo/ OLE Rimegepant
Number of Participants With ALT or AST Elevations >3*ULN Concurrent With TBL Elevations >2*ULN On-Treatment During the OLE Phase00
SecondaryNumber of Participants With Hepatic-related AEs On-Treatment During the DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with hepatic-related AEs during the DBT phase were reported.

Time frame:
From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Hepatic-related AEs On-Treatment During the DBT Phase
ParticipantsDBT RimegepantDBT Placebo
Number of Participants With Hepatic-related AEs On-Treatment During the DBT Phase2625
SecondaryNumber of Participants With Hepatic-related AEs Leading to Study Intervention Discontinuation On-Treatment During the DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with hepatic-related AEs leading to discontinuation of study intervention during the DBT phase were reported.

Time frame:
From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Hepatic-related AEs Leading to Study Intervention Discontinuation On-Treatment During the DBT Phase
ParticipantsDBT RimegepantDBT Placebo
Number of Participants With Hepatic-related AEs Leading to Study Intervention Discontinuation On-Treatment During the DBT Phase10
SecondaryNumber of Participants With Hepatic-related AEs On-Treatment During the OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with hepatic-related AEs during the OLE phase were reported.

Time frame:
From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Hepatic-related AEs On-Treatment During the OLE Phase
ParticipantsDBT Rimegepant/ OLE RimegepantDBT Placebo/ OLE Rimegepant
Number of Participants With Hepatic-related AEs On-Treatment During the OLE Phase2114
SecondaryNumber of Participants With Hepatic-Related AEs Leading to Study Intervention Discontinuation On-Treatment During the OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with hepatic-related AEs leading to discontinuation of study intervention during the OLE phase were reported.

Time frame:
From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Hepatic-Related AEs Leading to Study Intervention Discontinuation On-Treatment During the OLE Phase
ParticipantsDBT Rimegepant/ OLE RimegepantDBT Placebo/ OLE Rimegepant
Number of Participants With Hepatic-Related AEs Leading to Study Intervention Discontinuation On-Treatment During the OLE Phase00

Adverse events

Collected over DBT Phase: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks); OLE Phase: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks); Follow-up phase: 4 weeks after DBT Phase or completion of the OLE phase. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DBT Rimegepant0/392 (0%)8/392 (2%)162/392 (41.3%)
DBT Placebo0/394 (0%)3/394 (0.8%)161/394 (40.9%)
DBT Rimegepant/ OLE Rimegepant0/360 (0%)5/360 (1.4%)118/360 (32.8%)
DBT Placebo/ OLE Rimegepant0/364 (0%)1/364 (0.3%)110/364 (30.2%)
DBT/OLE Rimegepant0/392 (0%)13/392 (3.3%)235/392 (59.9%)
Follow-up: Rimegepant0/376 (0%)3/376 (0.8%)10/376 (2.7%)
Follow-up: DBT Placebo0/16 (0%)0/16 (0%)1/16 (6.3%)
Follow-up: DBT Placebo/OLE Rimegepant0/353 (0%)1/353 (0.3%)4/353 (1.1%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventDBT RimegepantDBT PlaceboDBT Rimegepant/ OLE RimegepantDBT Placebo/ OLE RimegepantDBT/OLE RimegepantFollow-up: RimegepantFollow-up: DBT PlaceboFollow-up: DBT Placebo/OLE Rimegepant
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/3920/3940/3600/3640/3920/3760/161/353
Arteriosclerosis coronary arteryCardiac disorders0/3920/3941/3600/3641/3920/3760/160/353
Tooth impactedGastrointestinal disorders0/3920/3941/3600/3641/3920/3760/160/353
Drug hypersensitivityImmune system disorders0/3920/3941/3600/3641/3920/3760/160/353
AppendicitisInfections and infestations0/3920/3941/3600/3641/3920/3760/160/353
Joint injuryInjury, poisoning and procedural complications0/3920/3941/3600/3641/3921/3760/160/353
Fibroadenoma of breastNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3920/3941/3600/3641/3920/3760/160/353
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3920/3940/3601/3640/3920/3760/160/353
GastritisGastrointestinal disorders1/3920/3940/3600/3641/3921/3760/160/353
Gastrointestinal mucosal disorderGastrointestinal disorders0/3920/3940/3600/3640/3921/3760/160/353
Most frequent other events
Showing 10 of 44
Most frequent other events
EventDBT RimegepantDBT PlaceboDBT Rimegepant/ OLE RimegepantDBT Placebo/ OLE RimegepantDBT/OLE RimegepantFollow-up: RimegepantFollow-up: DBT PlaceboFollow-up: DBT Placebo/OLE Rimegepant
Upper respiratory tract infectionInfections and infestations48/39251/39439/36025/36479/3926/3760/164/353
Protein urine presentInvestigations20/39214/3947/36014/36426/3920/3760/160/353
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3920/3940/3600/3640/3920/3761/160/353
ProteinuriaRenal and urinary disorders6/39219/3946/3605/36411/3920/3760/160/353
Urinary tract infectionInfections and infestations15/3925/3944/3606/36418/3920/3760/160/353
PyrexiaGeneral disorders9/3925/3948/3605/36416/3920/3760/160/353
InfluenzaInfections and infestations8/3929/3948/3600/36416/3920/3760/160/353
NasopharyngitisInfections and infestations11/39211/3944/3607/36415/3920/3760/160/353
Alanine aminotransferase increasedInvestigations11/39212/3945/3604/36415/3920/3760/160/353
Blood creatine phosphokinase increasedInvestigations11/3925/3942/3605/36413/3920/3760/160/353

Baseline characteristics

DBT safety set included participants in the enrolled analysis set who took \>=1 dose of double-blind study intervention (rimegepant or placebo).

Age, Continuous
Age, Continuous(Years)DBT RimegepantDBT PlaceboTotal
Mean37.5 ± 9.3436.9 ± 9.3237.2 ± 9.33
Sex: Female, Male
Sex: Female, Male(Participants)DBT RimegepantDBT PlaceboTotal
Female272299571
Male12095215
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DBT RimegepantDBT PlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino392394786
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DBT RimegepantDBT PlaceboTotal
American Indian or Alaska Native000
Asian392394786
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

49 sites
  • The Second People's hospital of Hefei
    Hefei, Anhui 230011, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing Municipality 100050, China
  • Chinese PLA General Hospital
    Beijing, Beijing Municipality 100853, China
  • The fourth people's hospital of chongqing
    Chongqing, Chongqing Municipality 400010, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400016, China
  • The 900th Hospital of Joint Logistics Support Force, PLA
    Fuzhou, Fujian 350025, China
  • Lanzhou university second hospital
    Lanzhou, Gansu 730030, China
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong 510180, China
  • Hainan General Hospital
    Haikou, Hainan 570311, China
  • Hebei General Hospital
    Shijiazhuang, Hebei 050051, China
  • People's Hospital of Zhengzhou
    Zhengzhou, Henan 450014, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
  • The First Affiliated Hospital of Baotou Medical College
    Baotou, Inner Mongolia 014010, China
  • The Second People's Hospital of Lianyungang
    Lianyungang, Jiangsu 222002, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • The Second Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215004, China
  • The First Affiliated Hospital of Suzhou University
    Suzhou, Jiangsu 215006, China
  • Wuxi People's Hospital
    Wuxi, Jiangsu 214023, China
  • Wuxi No. 2 People's Hospital
    Wuxi, Jiangsu 214043, China
  • Subei People's Hospital of Jiangsu province
    Yangzhou, Jiangsu 225001, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212001, China
  • Pingxiang People's Hospital
    Pingxiang, Jiangxi 337055, China
  • The First hospital of Jilin University
    Changchun, Jilin 130000, China
  • The Second Hospital of Jilin University
    Changchun, Jilin 130000, China
  • The People's Hospital of Liaoning Province
    Shenyang, Liaoning 110067, China
  • General Hospital of Ningxia Medical Hospital
    Yinchuan, Ningxia 750003, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710061, China
  • Shaanxi Provincial People's Hospital
    Xi'an, Shaanxi 710068, China
  • Xianyang Hospital of Yan'an University
    Xianyang, Shaanxi 712000, China
  • Shengli Oilfield Central Hospital
    Dongying, Shandong 257099, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Affiliated Hospital of Jining Medical University
    Jining, Shandong 272000, China
  • Liaocheng people's Hospital
    Liaocheng, Shandong 252000, China
  • Linyi People's Hospital
    Linyi, Shandong 276034, China
  • Qingdao Central Hospital
    Qingdao, Shandong 266042, China
  • People's Hospital of Rizhao
    Rizhao, Shandong 276800, China
  • Huashan Hospital Fudan University
    Shanghai, Shanghai Municipality 200040, China
  • Shanghai East Hospital
    Shanghai, Shanghai Municipality 200123, China
  • The First Hospital of Shanxi Medical University
    Taiyuan, Shanxi 030001, China
  • The Second Affiliated hospital of Kunming Medical University
    Kunming, Yunnan 650000, China
  • First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
  • Sir Run Run Shaw Hospital
    Hangzhou, Zhejiang 310016, China
  • The First Affiliated Hosptial of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
  • Peking University People's Hospital
    Beijing, 100044, China
  • Heping Hospital Affiliated to Changzhi Medical College
    Changzhi, 046000, China
  • Chongqing University Three Gorges Hospital
    Chongqing, 404000, China
  • Tianjin Union Medical Center
    Tianjin, 300000, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Aug 2025, 27 months.

Results were first posted in Sep 2026, 1 year after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 27 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2023
First posted
Apr 12, 2023
StartActual
May 15, 2023
Primary completionActual
Aug 25, 2025
CompletionActual
Dec 10, 2025
Results first posted
Sep 3, 2026
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05810038
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 12, 2023
Start date
May 15, 2023
Primary completion
Aug 25, 2025
Completion
Dec 10, 2025
Results posted
Sep 3, 2026
Last update
Sep 3, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimegepant

Start the discussion